Drugs Xagena
Ruxolitinib ( Jakafi ) is an oral, selective inhibitor of Janus kinases 1 and 2 ( JAK1 and JAK2 ). Ruxolitinib, brand name Jakafi, is indicated for treatment of patients with intermediate or high-risk ...
The U.S. Food and Drug Administration ( FDA ) has approved Jakafi ( Ruxolitinib ) for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. Jakafi is the f ...
The FDA ( Food and Drug Administration ) has approved Opzelura ( Ruxolitinib) cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is a ...
